Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 2007, p. 4502-4504, Vol. 51, No. 12
0066-4804/07/$08.00+0 doi:10.1128/AAC.00933-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Time of Incubation for Antifungal Susceptibility Testing of Aspergillus fumigatus: Can MIC Values Be Obtained at 24 Hours?
Juan Luis Rodriguez-Tudela,*
Laura Alcazar-Fuoli,
Ana Alastruey-Izquierdo,
Araceli Monzon,
Emilia Mellado, and
Manuel Cuenca-Estrella
Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Majadahonda, Spain
Received 19 July 2007/
Returned for modification 6 September 2007/
Accepted 2 October 2007

ABSTRACT
A collection of
Aspergillus fumigatus isolates was used to check
if MICs can be read at 24 h. At 24 h, the geometric mean MIC
of itraconazole for resistant isolates was determined to be
5.11 mg/liter, but the MIC was read as 16 mg/liter at 48 h.
At 24 h, MICs for 51.5% of resistant strains were determined
to be

2 mg/liter. MICs must be obtained at 48 h.

TEXT
The incidence of invasive mold infections has increased in the
last decades. The mortality due to these infections is very
high, and outcomes are determined mainly by the risk factors
of the patients. Although the correlation between the results
of antifungal susceptibility testing and the outcomes for patients
is far from perfect, several reports have described poorer responses
to therapy by those infections caused by isolates for which
MICs are high. Lass-Flörl et al. (
11) reported favorable
outcomes for 20% of patients with invasive disease caused by
Aspergillus terreus who were treated with amphotericin B, in
comparison with 47% of amphotericin B-treated patients with
disease caused by other
Aspergillus spp. The amphotericin B
MICs for
A. terreus have been shown to be higher than those
for
A. fumigatus (
11,
20), and therefore, the poorer responses
of patients were attributed to higher amphotericin B MICs. In
addition, resistant strains of
A. fumigatus have recently been
reported (
2-
5,
8,
13,
14,
21).
Antifungal susceptibility testing has been standardized for molds (16). The optimal susceptibility testing conditions for the detection of azole-resistant strains were defined by Espinel-Ingroff et al. (6). The recommendation was to estimate the end point as the complete inhibition of visual fungal growth at 48 h. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) started the standardization of the antifungal susceptibility testing of molds, and now the standard is pending final approval (10). In previous work (7), we observed that the time of incubation significantly affected the final MIC readings and that sometimes a major increase (two to six dilutions) occurred between readings at 24 and 48 h. Most A. fumigatus strains are capable of growth in RPMI 1640 within 24 h. Thus, there is a chance to obtain end points at 24 h and deliver the results to the clinicians at an earlier time.
The aim of this study was to check if the MICs of antifungal drugs for A. fumigatus can be read at 24 h instead of at 48 h. To achieve this, we have compared a large collection of clinical isolates of A. fumigatus for which MICs of azole drugs vary from low to high.
Microorganisms.
One hundred fifty itraconazole-susceptible A. fumigatus strains and 33 A. fumigatus strains resistant to itraconazole were included. The mechanisms of resistance of these strains have been described previously (5, 12-15).
Antifungal susceptibility testing.
Microdilution testing was performed by following the EUCAST methodology (10). This standard is similar to approved standard M38-A published by the Clinical and Laboratory Standards Institute (CLSI; formerly the National Committee for Clinical Laboratory Standards) (16), with the following modifications: (i) RPMI 1640 is supplemented with glucose to reach a 2% concentration, (ii) the inoculum size is between 2 x 105 and 5 x 105 CFU/ml, and (iii) inocula are prepared by counting spores in a hematocytometer (1, 18, 19). A. fumigatus ATCC 204305 and A. flavus ATCC 204304 were used as quality control strains (16).
The antifungal agents used were amphotericin B (range, 0.03 to 16 mg/liter; Sigma Aldrich Química), itraconazole (range, 0.015 to 8 mg/liter; Janssen S.A.), voriconazole (range, 0.015 to 8 mg/liter; Pfizer S.A.), ravuconazole (range, 0.015 to 8 mg/liter; Bristol-Myers Squibb), and posaconazole (range, 0.015 to 8 mg/liter; Schering-Plough Research Institute).
End points were recorded at 24 and 48 h and defined as the antifungal concentration that produced a complete inhibition of visual growth. MICs for resistant strains were determined at least two times on different days (range of repetitions, 2 to 11).
Statistical calculations.
Statistical analysis was done with the Statistical Package for the Social Sciences (version 15.0; SPSS S.L). Both on-scale and off-scale results were included in the analysis. The off-scale MICs were converted to the next concentration up or down.
Table 1 shows the geometric mean (GM) MICs and the ranges obtained at 24 and 48 h for susceptible and itraconazole-resistant isolates. For all itraconazole-resistant isolates, the GM MIC of itraconazole was 16 mg/liter at 48 h. However, at 24 h the GM MIC was 5.11 mg/liter, and itraconazole MICs for some strains were as low as 0.25 mg/liter. This result was not isolate dependent but rather due to the poor reproducibility of MICs read at 24 h for itraconazole-resistant strains. As the testing of all isolates was repeated at least two times, the analyses of the MICs obtained at 24 h showed that MICs for 17 (51.5%) of 33 itraconazole-resistant strains were read as
2 mg/liter at least once. For susceptible strains, the 24-h GM was 0.16 mg/liter and the 48-h GM was 0.33 mg/liter (Table 1). For voriconazole, ravuconazole, and posaconazole, the differences were less striking, and GMs showed one twofold-dilution difference between 24- and 48-h readings (Table 1) for all strains tested. As exceptions, there was one isolate not growing at 24 h and MICs of posaconazole for two further isolates were shown to be 2 mg/liter at 24 h and 16 mg/liter at 48 h.
View this table:
[in this window]
[in a new window]
|
TABLE 1. GM MICs and ranges of MICs (mg/liter) obtained at 24 and 48 h for azole drug-susceptible and -resistant A. fumigatus isolates
|
In this study, the MICs for a large collection of susceptible
and itraconazole-resistant strains of
A. fumigatus have been
analyzed and the results obtained at 24 and 48 h have been compared.
Several articles have associated poor outcomes for patients
with infections caused by isolates or species for which MICs
are high (
9,
11,
17,
20). Therefore, the quick detection of
resistant isolates can influence the outcome for the patient,
allowing a prompt change of the antifungal treatment. The growth
of most clinical isolates of
A. fumigatus is apparently adequate
at 24 h in antifungal susceptibility testing microplates with
RPMI 1640-2% glucose. Furthermore, we have used an inoculum
size of 2
x 10
5 to 5
x 10
5 CFU/ml, 10-fold larger than the one
recommended by CLSI document M38-A. This inoculum provided better
growth of
A. fumigatus than smaller inocula, making the visual
estimation of the end point straightforward. Our results do
no support reading end points at 24 h because MICs for 51.5%
of the itraconazole-resistant strains were determined to be

2 mg/liter at least once at that time point. As itraconazole
MICs for some isolates were as high as 16 mg/liter at 24 h,
one may consider the possibility of accepting the results for
these isolates at 24 h. However, we detected such high MICs
of itraconazole for two isolates at 24 h but posaconazole MICs
of 2 mg/liter at 24 h and 16 mg/liter at 48 h.
In summary, the detection of resistant strains of A. fumigatus by means of EUCAST-standardized antifungal susceptibility testing for molds requires 48 h of incubation. Too many false-negative results for resistant strains were detected at 24 h, making MIC reading at this time point unreliable.

ACKNOWLEDGMENTS
This work was funded in part by grants MPY1175/06 and PI05/32
from the Instituto de Salud Carlos III and SAF2005-06541 from
the Ministerio de Educacion y Ciencia and by the Spanish Network
for Research in Infectious Diseases (REIPI RD06/0008). L. Alcazar-Fuoli
holds a postdoctoral contract from the EU-STREP project (LSHM-CT-2005-518199).
A. Alastruey-Izquierdo holds a predoctoral fellowship from Fondo
de Investigaciones Sanitarias (grant FI05/00856).

FOOTNOTES
* Corresponding author. Mailing address: Servicio de Micologia, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo km 2, 28220 Majadahonda, Spain. Phone: 34 91 822 3919. Fax: 34 91 509 7966. E-mail:
jlrtudela{at}isciii.es 
Published ahead of print on 15 October 2007. 

REFERENCES
1 - Aberkane, A., M. Cuenca-Estrella, A. Gomez-Lopez, E. Petrikkou, E. Mellado, A. Monzon, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi. J. Antimicrob. Chemother. 50:719-722.[Abstract/Free Full Text]
2 - Chen, J., H. Li, R. Li, D. Bu, and Z. Wan. 2005. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J. Antimicrob. Chemother. 55:31-37.[Abstract/Free Full Text]
3 - Dannaoui, E., E. Borel, M. F. Monier, M. A. Piens, S. Picot, and F. Persat. 2001. Acquired itraconazole resistance in Aspergillus fumigatus. J. Antimicrob. Chemother. 47:333-340.[Abstract/Free Full Text]
4 - Dannaoui, E., D. Garcia-Hermoso, J. M. Naccache, I. Meneau, D. Sanglard, C. Bouges-Michel, D. Valeyre, and O. Lortholary. 2006. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus. J. Med. Microbiol. 55:1457-1459.[Abstract/Free Full Text]
5 - Diaz-Guerra, T. M., E. Mellado, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2003. A point mutation in the 14
-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.[Abstract/Free Full Text] 6 - Espinel-Ingroff, A., M. Bartlett, V. Chaturvedi, M. Ghannoum, K. C. Hazen, M. A. Pfaller, M. Rinaldi, and T. J. Walsh. 2001. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. Antimicrob. Agents Chemother. 45:1828-1835.[Abstract/Free Full Text]
7 - Gomez-Lopez, A., A. Aberkane, E. Petrikkou, E. Mellado, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2005. Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp. J. Clin. Microbiol. 43:1251-1255.[Abstract/Free Full Text]
8 - Howard, S. J., I. Webster, C. B. Moore, R. E. Gardiner, S. Park, D. S. Perlin, and D. W. Denning. 2006. Multi-azole resistance in Aspergillus fumigatus. Int. J. Antimicrob. Agents 28:450-453.[CrossRef][Medline]
9 - Kontoyiannis, D. P., G. P. Bodey, H. Hanna, R. Hachem, M. Boktour, E. Girgaway, M. Mardani, and I. I. Raad. 2004. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk. Lymphoma 45:139-141.[CrossRef][Medline]
10 - Lass-Florl, C., M. Cuenca-Estrella, D. W. Denning, and J. L. Rodriguez-Tudela. 2006. Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology. Med. Mycol. 44:S319-S325.[CrossRef]
11 - Lass-Florl, C., K. Griff, A. Mayr, A. Petzer, G. Gastl, H. Bonatti, M. Freund, G. Kropshofer, M. P. Dierich, and D. Nachbaur. 2005. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br. J. Haematol. 131:201-207.[CrossRef][Medline]
12 - Mellado, E., T. M. Diaz-Guerra, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2001. Identification of two different 14-
sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438.[Abstract/Free Full Text] 13 - Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2004. Substitutions at methionine 220 in the 14
-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.[Abstract/Free Full Text] 14 - Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, W. J. G. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.[Abstract/Free Full Text]
15 - Mellado, E., G. Garcia-Effron, M. J. Buitrago, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2005. Targeted gene disruption of the 14-
sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob. Agents Chemother. 49:2536-2538.[Abstract/Free Full Text] 16 - National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
17 - Perfect, J. R., K. A. Marr, T. J. Walsh, R. N. Greenberg, B. Dupont, J. Torre-Cisneros, G. Just-Nubling, H. T. Schlamm, I. Lutsar, A. Espinel-Ingroff, and E. Johnson. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.[CrossRef][Medline]
18 - Petrikkou, E., J. L. Rodriguez-Tudela, M. Cuenca-Estrella, A. Gomez, A. Molleja, and E. Mellado. 2001. Inoculum standardization for antifungal susceptibility testing of filamentous fungi pathogenic for humans. J. Clin. Microbiol. 39:1345-1347.[Abstract/Free Full Text]
19 - Rodriguez-Tudela, J. L., E. Chryssanthou, E. Petrikkou, J. Mosquera, D. W. Denning, and M. Cuenca-Estrella. 2003. Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi. J. Clin. Microbiol. 41:5236-5237.[Abstract/Free Full Text]
20 - Steinbach, W. J., J. R. Perfect, W. A. Schell, T. J. Walsh, and D. K. Benjamin, Jr. 2004. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob. Agents Chemother. 48:3217-3225.[Free Full Text]
21 - Trama, J. P., E. Mordechai, and M. E. Adelson. 2005. Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing. J. Clin. Microbiol. 43:906-908.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, December 2007, p. 4502-4504, Vol. 51, No. 12
0066-4804/07/$08.00+0 doi:10.1128/AAC.00933-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Alastruey-Izquierdo, A., Castelli, M. V., Cuesta, I., Monzon, A., Cuenca-Estrella, M., Rodriguez-Tudela, J. L.
(2009). Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers. Antimicrob. Agents Chemother.
53: 1686-1689
[Abstract]
[Full Text]
-
Rodriguez-Tudela, J. L., Alcazar-Fuoli, L., Mellado, E., Alastruey-Izquierdo, A., Monzon, A., Cuenca-Estrella, M.
(2008). Epidemiological Cutoffs and Cross-Resistance to Azole Drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother.
52: 2468-2472
[Abstract]
[Full Text]
-
Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., Perlin, D. S.
(2008). Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus. J. Clin. Microbiol.
46: 1200-1206
[Abstract]
[Full Text]